Begin typing your search above and press return to search.
Volume: 18 Issue: 5 October 2020


Successful Treatment of Idiopathic Thrombocytopenic Purpura After Liver Transplant: A Case Report

Idiopathic thrombocytopenic purpura, a common acquired bleeding disorder in pediatric patients, is an autoimmune disorder characterized by a low platelet count. Organ transplant can transfer such diseases, but the occurrence of idiopathic thrombocytopenic purpura after liver transplant is rare. Here, we report a 17-month-old girl who was diagnosed with idiopathic thrombocytopenic purpura and who had a history of liver transplant 11 months earlier. Treatment of cytomegalovirus and Epstein-Barr virus infection led to a successful outcome.

Key words : Cytomegalovirus, Epstein-Barr virus, Platelets, Thrombocytopenia


Idiopathic (Immune) thrombocytopenic purpura (ITP), a common acquired bleeding disorder of childhood, is a heterogeneous autoimmune syndrome characterized by the production of antiplatelet antibodies against circulating platelets, resulting in destruction and reduced platelet count (< 100 × 109/L) followed by an increased risk of bleeding.1,2 In children, ITP may be triggered by a viral infection, usually 3 weeks before presentation, in 50% to 65% of affected cases.3 Bleeding symptoms can be variable, from mild without need for treatment to severe requiring urgent treatment.4 Overall, the first line of therapy for acute ITP is corticosteroids, and the second choice is intravenous immunoglobulin (IVIG) or intravenous anti-D immunoglobulin.1 A small subset of patients may not respond to standard treatment; therefore, their care is a matter of debate because there is no consensus regarding how to proceed with treatment in such refractory cases.5 Patients with a history of organ transplant who are treated with immunosuppressive drugs have a relatively low immune reactivity, which makes them more vulnerable to aggressive agents, microorganisms, and especially viruses.6 The causes for reduced numbers of platelets in patients under­going liver transplant are complex, not completely understood, and likely to be multifactorial.7 Here, we report the successful treatment of ITP after liver transplant with antiviral medication.

Case Report

A 17-month-old girl was admitted with signs of petechiae and ecchymosis to a tertiary hospital. Physical examination on admission showed that the patient did not have any signs of fever or chills and no history of infection; in addition, her vital signs were normal. Examinations of the lungs and heart were also within normal limits. Petechiae and ecchymosis were observed on the head, face, and chest, but the patient had no organomegaly or lymphadenopathy. The patient had a liver transplant surgery 11 months previously because of decom­pensated cirrhosis and multiple hepatic nodules due to tyrosinemia type 1. She underwent living related liver transplant with blood group B-positive and body weight of 11.5 kg from her mother with B-negative blood group. The patient’s posttransplant period was uneventful, and she showed normal graft function. After transplant, the patient had received prophylactic valganciclovir (150 mg/day) for 3 months and cotrimoxazole (2 mg/kg) every night. Immunosuppressive agents included tacrolimus (2 mg) twice per day and prednisolone (5 mg) every other day.

On the day of admission, the patient had melena, with positive guaiac-based fecal occult blood test. Her complete blood count results showed a platelet count of 5 × 109/L. Procalcitonin level was 0.24 (normal range of ≤ 0.15 ng/mL), and her C-reactive protein level was 5 (normal range of < 6 mg/l). The patient’s liver function test was normal. Serum lactate dehydrogenase was high (1246 IU/L), and urine analysis showed trace amounts of blood. Blood culture results were negative. A color Doppler sonography scan of the portal system and hepatic veins showed normal flow, but the spleen was prominent in size 11 months after liver transplant.

Blood samples for cytomegalovirus (CMV), Epstein-Barr virus (EBV), and parvovirus B19 infections were obtained for polymerase chain reaction (PCR) tests. Because of the likelihood of drug-induced thrombocytopenia, cotrimoxazole was discontinued and tacrolimus dose was reduced to 1 mg/day.

Bone marrow aspiration and trephine biopsy were performed to rule out posttransplant lymph­oproliferative disorder. The results showed normal cellular marrow with increased numbers of megakaryocytes in favor of ITP (Figure 1). The results of bone marrow flow cytometry indicated the presence of 2% of immature myeloid cells and about 4% of hematogones, which was not suggestive of malignancy. With the possibility of ITP, daily methylprednisolone (30 mg/kg) was given for 3 consecutive days. Despite methylprednisolone therapy, the patient’s platelet count was still extremely low (2 × 109/L). Because the patient’s platelet count was critically low, this was considered as an emergency situation. Therefore, daily IVIG (1 g/kg) for 2 days was immediately given. The patient’s platelet count rose slightly but without dramatic response, showing a level of 7 × 109/L (14 days after start of bleeding symptoms).

On day 15 after IVIG administration, the patient showed no durable response to routine therapy. The PCR tests showed negative parvovirus PCR results; however, EBV and CMV PCR results showed positive plasma levels of 185 000 copies/mL and 5400 copies/mL, respectively. Therefore, intravenous acyclovir was started for 2 weeks followed by oral administration for 31 days (at which time both PCR tests became negative for the second time).

On day 36, liver enzymes had increased (aspartate aminotransferase [AST] of 169 U/L, alanine aminotransferase [ALT] of 400 U/L, and alkaline phosphatase [ALP] of 1026 U/L). Causes of elevated liver enzymes were investigated with sonography of transplanted liver. Results revealed no signs of biliary tract abnormality or parenchymal damage. A color Doppler sonography of the portal system and the hepatic vein was also conducted, which showed normal conditions 12 months after liver transplant.

Because the patient’s tacrolimus level was 5.8 ng/mL, her dose was returned to 2 mg twice daily. Liver biopsy was not amenable due to low platelet count; however, we suspected acute rejection owing to liver function disturbance due to decreases in immunosuppressant drugs. Therefore, daily intravenous methylprednisolone (30 mg/kg) for 3 days was prescribed for the patient followed by oral prednisolone at 2 mg/kg per day instead of 0.7 mg/kg per day.

Up to day 44, her liver enzyme levels improved slightly, with AST of 45 U/L, ALT of 120 U/L, and ALP of 480 U/L. However, they elevated again on postadmission day 45 (AST of 312 U/L, ALT of 398 U/L, ALP of 823 U/L); therefore, administration of everolimus was started. Changes in liver enzyme values are shown in Figure 2.

Twenty-five days after starting antiviral medication (day 40), PCR results for EBV and CMV infection showed negative results. Another set of negative results were documented on day 55.

The patient’s platelet count increased on postadmission day 58 to 102 × 109/L following full treatment of viral infection, with liver function tests showing normal results after treatment with everolimus. Regular follow-up showed continued elevations in platelet count until month 3 after discharge, at which time prednisolone was tapered to 0.5 mg/kg per day (Figure 2).


Idiopathic thrombocytopenic purpura is a common pediatric hematology disorder characterized by a low platelet count and increased risk of muco­cutaneous bleeding.2 It is usually classified into 2 forms: primary, which is idiopathic in origin, and secondary, which is caused by variety of factors. These factors include drugs, malignancies, infections such as acute viral infections, and live attenuated virus vaccination, as well as chronic infections like parvovirus and CMV.4,8,9 In a study by Shimanovsky and associates, CMV-associated ITP was shown to result in severe refractory thrombocytopenia that was unresponsive to standard therapy.5

Organ transplant procedures may transfer ITP from donor to recipient. A review of the literature has shown occurrences of ITP after liver transplant. Assy and associates reported a 12-year-old boy who presented with ITP 2 years after liver transplant as a result of decompensated liver cirrhosis due to Wilson disease. The laboratory findings in this case indicate parvovirus B19 infection.10 Pereboom and associates reported a patient with ITP during orthotopic liver transplant. In this case, the organ donor died from a serious intracranial hemorrhage resulting from acute ITP.  A similar case about transmission of ITP during liver transplant from a donor with ITP was reported by Diaz and associates.12

In another report, a 3-year-old boy with a history of liver transplant (donor was his mother and transplant was due to biliary atresia at the age of 11 months) experienced acute ITP 2 years after transplant, with cause indicated as CMV infection. The patient was cured with IVIG treatment.6 Mitsuhisa and associates examined ITP within a cohort of 266 patients who had living related liver transplant. They found 3 cases of ITP after liver transplant, which occurred 1 day (patient 1), 3 months (patient 2), and 13 months (patient 3) after transplant. Reason for transplant was biliary atresia in all 3 cases. Patient 1 had a history of CMV infection before transplant. The mother of patient 2, who was the donor, had a history of pregnancy-related ITP. Patient 3 had no history of viral infection. All 3 patients with ITP were cured with IVIG.13 In another report, Taylor and associates evaluated ITP cases in patients with a history of liver transplant. In this report, the overall occurrence of ITP over a period of 15 years, which included 1105 liver transplant recipients, was 0.7% (8 patients). The average age of onset of ITP was 54 years (range, 15-63 y), and the average time period from liver transplant to first occurrence of ITP was 5.53 months (range, 9.1-173 mo). Most of these patients were cured with IVIG administration.7

Although most of the reported patients with ITP responded to routine therapy (immunosuppressant and IVIG), one patient reported by Arnold and associates required an antiviral drug (ganciclovir) for full recovery.14

Our patient also showed ITP after liver trans­plant, which was diagnosed by acute onset of thrombocytopenia and increased numbers of megakaryocytes in bone marrow aspiration. The patient did not respond to routine treatment with IVIG and intravenous methylprednisolone pulse therapy. We concluded that EBV and CMV infection can play an important role in the occurrence of ITP after liver transplant and ITP can be refractory to standard therapy. For these patients, a course of antiviral therapy should be considered.


  1. Hsia CC, Liu Y, Eckert K, Monga N, Elia-Pacitti J, Heddle NM. Intravenous immunoglobulin (IVIg) Utilization in immune thrombocytopenia (ITP): a multi-center, retrospective review. Drugs Real World Outcomes. 2015;2(1):35-42.
  2. Fujino S, Niwa S, Fujioka K, et al. Primary percutaneous coronary intervention by a stentless technique for acute myocardial infarction with idiopathic thrombocytopenic purpura: a case report and review of the literature. Intern Med. 2016;55(2):147-152.
  3. Akbayram S, Akgun C, Dogan M, Caksen H, Oner AF. Acute ITP due to insect bite: report of 2 cases. Clin Appl Thromb Hemost. 2011;17(4):408-409.
  4. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186.
  5. Shimanovsky A, Patel D, Wasser J. Refractory immune thrombocytopenic purpura and cytomegalovirus infection: a call for a change in the current guidelines. Mediterr J Hematol Infect Dis. 2016;8(1):e2016010.
  6. Wei SH, Ho MC, Ni YH, Lin DT, Lee PH. Cytomegalovirus-associated immune thrombocytopenic purpura after liver transplantation. J Formos Med Assoc. 2007;106(4):327-329.
  7. Taylor RM, Bockenstedt P, Su GL, Marrero JA, Pellitier SM, Fontana RJ. Immune thrombocytopenic purpura following liver transplantation: a case series and review of the literature. Liver Transpl. 2006;12(5):781-791.
  8. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207.
  9. Tahir H, Sheraz F, Sagi J, Daruwalla V. Immune Thrombocytopenia (ITP) secondary to subclinical Hashimoto's thyroiditis: role of levothyroxine in improving the clinical outcome of ITP. J Investig Med High Impact Case Rep. 2016;4(2):2324709616647085.
  10. Assy N, Rosenthal E, Hazani A, Etzioni A, Baruch Y. Human parvovirus B19 infection associated with idiopathic thrombocytopenic purpura in a child following liver transplantation. J Hepatol. 1997;27(5):934-936.
  11. Pereboom IT, de Boer MT, Haagsma EB, et al. Transmission of idiopathic thrombocytopenic purpura during orthotopic liver transplantation. Transpl Int. 2010;23(2):236-238.
  12. Diaz GC, Prowda J, Lo IJ, et al. Transplantation-mediated alloimmune thrombocytopenia: Guidelines for utilization of thrombocytopenic donors. Liver Transpl. 2008;14(12):1803-1809.
  13. Takatsuki M, Uemoto S, Kurokawa T, Koshiba T, Inomata Y, Tanaka K. Idiopathic thrombocytopenic purpura after a living-related liver transplantation. Transplantation. 1999;67(3):479-481.
  14. Arnold JC, Heilig B, Otto G, Kommerell B, Theilmann L. Cytomegalovirus-induced severe thrombocytopenia after liver transplantation. Transplantation. 1993;56(5):1286-1288.

Volume : 18
Issue : 5
Pages : 649 - 652
DOI : 10.6002/ect.2018.0083

PDF VIEW [1816] KB.

From the 1Student Research Committee, the 2Department of Pediatric Gastroenterology, Gastroenterohepatology Research Center of Nemazee Hospital, the 3Gastroenterohepatology Research Center, and the 4Transplant Research Center, Nemazee Hospital; Shiraz University of Medical Science, Shiraz, Iran
Acknowledgements: The authors have no sources of funding for this study and have no conflicts of interest to declare. The authors thank the patient and her family.
Corresponding author: Mohammad Hadi Imanieh, Department of Pediatric Gastroenterology, Gastroenterohepatology Research Center of Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Phone: +98 71 32352559